Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an update.
Shanghai Junshi Biosciences Co., Ltd. has announced the proposed election of Dr. Yang Jin as an independent non-executive director, subject to shareholder approval at an upcoming extraordinary general meeting. This change follows the resignation of Dr. Yang Yue from the same position due to other work commitments. The company is also adjusting the composition of its Remuneration and Appraisal Committee and Nomination Committee. These changes are part of the company’s ongoing efforts to strengthen its board and governance structure.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative therapies for cancer, autoimmune, and infectious diseases.
Average Trading Volume: 13,577,005
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.42B
For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.